CN113068747A - Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants - Google Patents
Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants Download PDFInfo
- Publication number
- CN113068747A CN113068747A CN202010213040.XA CN202010213040A CN113068747A CN 113068747 A CN113068747 A CN 113068747A CN 202010213040 A CN202010213040 A CN 202010213040A CN 113068747 A CN113068747 A CN 113068747A
- Authority
- CN
- China
- Prior art keywords
- milk powder
- pregnant
- lying
- women
- formula milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
Abstract
The embodiment of the invention relates to the field of foods, and particularly relates to a formula milk powder for pregnant and lying-in women, which can promote the health of the pregnant and lying-in women and infants. Every 100g of the formula milk powder for pregnant and lying-in women provided by the embodiment of the invention comprises the following components: 4-9g of oligosaccharide and 1-7g of casein glycomacropeptide. The formula milk powder for pregnant and lying-in women provided by the invention creatively adds a certain amount of casein glycomacropeptide which is a bioactive substance with special functions, and is beneficial to improving the health of the pregnant and lying-in women; the milk powder is rich in sialic acid, so that the content of sialic acid in the formula milk powder for pregnant and lying-in women is far higher than that of the existing milk powder for pregnant women, and the milk powder is more favorable for promoting the intelligence development and growth development of infants; meanwhile, due to the addition of the oligosaccharide, the intestinal micro-ecological health of the pregnant and lying-in women can be promoted, and the components of the formula milk powder of the pregnant and lying-in women are close to the serum and breast milk in the pregnancy period, so that the growth and development of fetuses and infants are promoted.
Description
Technical Field
The invention relates to the field of foods, in particular to a formula milk powder for pregnant and lying-in women, which can promote the health of pregnant and lying-in women and infants.
Background
Casein Glycomacropeptide (CGMP) is a sialic acid-containing glycopeptide discovered in 1965 and is produced by hydrolyzing k-Casein with chymosin during cheese making. More than 90% of the sugar chains of CGMP contain sialic acid. Research shows that the biological activity of CGMP is related to sialic acid, and meanwhile, the CGMP has the functional characteristics of inhibiting adhesion of bacteria and viruses, promoting proliferation of bifidobacteria, regulating an immune system, combining escherichia coli toxin and cholera toxin and the like, is rich in biological activity and nutritional characteristics, and is widely concerned in the fields of medicines and health-care foods. However, no study on the effect of casein glycomacropeptide on pregnant and lying-in women is found so far, and no report on the artificial addition of casein glycomacropeptide in formula milk powder of pregnant and lying-in women is found. The commercial milk powder for pregnant and lying-in women only contains trace casein glycomacropeptide contained in milk powder raw material, and the content of the casein glycomacropeptide in every 100g of milk powder is only 0.005g-0.05 g.
Sialic Acid (SA), known under the chemical name "N-acetylneuraminic acid", is a naturally occurring carbohydrate, originally isolated from submandibular gland mucin and is therefore named.
Galacto-oligosaccharides (GOS) are functional oligosaccharides with natural properties, typically having a molecular structure comprising 1-7 galactosyl groups attached to galactose or glucose molecules, i.e. Gal- (Gal) n-Glc/Gal (n is 0-6). Fructooligosaccharide (FOS), also called Fructooligosaccharide, is a mixture of kestose, nystose, and nystose, etc., which is formed by combining 1-3 fructose groups with fructose groups in sucrose through beta-fructose groups and through glycosidic bonds. Both GOS and FOS have a positive effect on the regulation of intestinal probiotics. The article shows that the pregnant women can obviously improve the intestinal micro-ecology by taking 8.1g of GOS and 0.9g of FOS every day in the period from 25 weeks of natural pregnancy to delivery, and totaling 9 g/d. However, the content of GOS in the commercially available milk powder for pregnant and lying-in women is generally low (less than 1g/100 g).
The information disclosed in this background section is only for enhancement of understanding of the general background of the invention and should not be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.
Disclosure of Invention
Object of the Invention
In order to solve the technical problems, the invention aims to provide the pregnant and lying-in woman formula milk powder for promoting the health of pregnant and lying-in women and infants. According to the formula milk powder for pregnant and lying-in women, a certain amount of casein glycomacropeptide which is a bioactive substance with special functions is creatively added into the formula milk powder for pregnant and lying-in women, so that the immunity of the pregnant and lying-in women can be enhanced, the intestinal micro-ecological health of the pregnant and lying-in women can be promoted, and the health of the pregnant and lying-in women can be promoted; in addition, due to the fact that the milk powder is rich in sialic acid, the formula milk powder for pregnant and lying-in women contains enough sialic acid (the sialic acid content of the milk powder is far higher than that of the existing milk powder for pregnant and lying-in women), and the intelligence development and the growth development of infants can be promoted; meanwhile, the oligosaccharide is added in a matched manner with the casein glycomacropeptide, so that on one hand, the oligosaccharide can promote the intestinal microecological health of the pregnant women, on the other hand, the sialic acid in the breast milk is mainly combined with the oligosaccharide, and the casein glycomacropeptide and the oligosaccharide are added in a matched manner, so that the components of the formula milk powder for the pregnant and lying-in women are close to the serum and the breast milk in the pregnancy period, and the growth and development of fetuses and infants are facilitated.
Solution scheme
In order to achieve the object of the present invention, an embodiment of the present invention provides a milk powder formula for pregnant and lying-in women, wherein each 100g of the milk powder formula for pregnant and lying-in women comprises: 1-7g of casein glycomacropeptide and 4-9g of oligosaccharide. The content of casein glycomacropeptide in the formula milk powder for pregnant and lying-in women is obviously higher than that of the existing milk powder for pregnant and lying-in women. The biological activity of CGMP is related to sialic acid, and the CGMP also has the functional characteristics of inhibiting adhesion of bacteria and viruses, promoting proliferation of bifidobacteria, regulating immune system, combining escherichia coli toxin and cholera toxin and the like. The invention discovers for the first time that the CGMP has obvious promotion effect on the body health of pregnant and lying-in women and the growth and development of fetuses and infants.
The formula milk powder for pregnant and lying-in women is prepared by taking components containing raw milk as raw materials, adding Casein Glycomacropeptide (CGMP) and oligosaccharide at external sources and drying; in each 100g of the maternal and maternal formula milk powder (dry powder), the total content of CGMP (dry weight) is 1-7g, and the total content of oligosaccharide (dry weight) is 4-9 g.
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women comprises, per 100g of the formula milk powder for pregnant and lying-in women: 2.5-5g of casein glycomacropeptide and 5-7g of oligosaccharide;
optionally, every 100g of the maternal formula milk powder comprises: 3-4g of casein glycomacropeptide and 6g of oligosaccharide.
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women comprises, per 100g of the formula milk powder for pregnant and lying-in women: sialic acid 0.25-0.4 g; alternatively 0.3 g. Sialic acid in the formula milk powder mainly comes from exogenously added casein glycomacropeptide, and every 100g of the formula milk powder comprises: sialic acid 0.25-0.4g "means that after exogenous addition of casein glycomacropeptide the total amount (dry weight) of sialic acid is 0.25-0.4g per 100g of the maternal formula (dry powder). Due to the addition of casein glycomacropeptide, the content of sialic acid in the formula milk powder for pregnant and lying-in women is obviously higher than that of the existing milk powder for pregnant and lying-in women.
In one possible implementation, the oligosaccharide comprises one or more of galacto-oligosaccharide (GOS) or fructo-oligosaccharide (FOS); optionally, the oligosaccharide is a galactooligosaccharide.
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women comprises, per 100g of the formula milk powder for pregnant and lying-in women: 0.25-0.4g of sialic acid and 4-9g of galacto-oligosaccharide. The GOS content of the formula milk powder for pregnant and lying-in women is obviously higher than that of the existing milk powder for pregnant and lying-in women.
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women comprises, per 100g of the formula milk powder for pregnant and lying-in women: sialic acid 0.3g, galacto-oligosaccharide 6 g.
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women further comprises, per 100g of the formula milk powder for pregnant and lying-in women: nicotinic acid, folic acid, vitamin A, vitamin D, vitamin K, vitamin B1 and docosahexaenoic acid (DHA).
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women further comprises, per 100g of the formula milk powder for pregnant and lying-in women: 5-6mg of nicotinic acid, 1000 mu g of folic acid 950-.
In a possible implementation manner, the above formula milk powder for pregnant and lying-in women further comprises, per 100g of the formula milk powder for pregnant and lying-in women: 5.6mg of nicotinic acid, 986 mu g of folic acid, 600 mu g of vitamin A, 6.0 mu g of vitamin D, 40.0 mu g of vitamin K, 11 mg of vitamin B and 37mg of docosahexaenoic acid (DHA).
In a possible implementation manner, the daily intake of the formula milk powder for pregnant and lying-in women is 60 g. The intake of 60g/d is the conventional recommended intake of the formula milk powder for pregnant and lying-in women, and when the recommended intake per day is changed, the contents of sialic acid, oligosaccharide and other components in each 100g of the formula milk powder for pregnant and lying-in women can be proportionally adjusted.
In a possible implementation manner, the formula milk powder for pregnant and lying-in women comprises the following total nutrient components:
the embodiment of the invention also provides a preparation method of the formula milk powder for pregnant and lying-in women, which comprises the following steps: the formula milk powder for pregnant and lying-in women is prepared by taking components including raw milk as raw materials and adding casein glycomacropeptide and oligosaccharide through a wet processing technology.
In one possible implementation form of the preparation method, the wet processing technology comprises the following steps:
checking and accepting the raw milk; feeding casein glycomacropeptide and oligosaccharide; homogenizing with homogenizer at 4-18 MPa; sterilizing at 85-97 deg.C, and concentrating; spray drying to obtain powder.
In one possible implementation form, the preparation method comprises the following steps: the formula milk powder for pregnant and lying-in women is prepared by taking components including raw milk as raw materials and adopting a processing technology shared by a wet method and a dry method, wherein the formula milk powder comprises the following components in parts by weight: docosahexaenoic acid (DHA) is added by a dry process, and the rest ingredients are added by a wet process.
In one possible implementation form, the preparation method comprises the following steps: checking and accepting the raw milk; feeding ingredients except for docosahexaenoic acid; homogenizing with homogenizer at 4-18 MPa; sterilizing at 85-97 deg.C, and concentrating; spray drying to obtain powder; adding docosahexaenoic acid into the obtained powder, and mixing.
Advantageous effects
(1) The formula milk powder for pregnant and lying-in women provided by the embodiment of the invention creatively adds a certain amount of bioactive substance with special function, namely casein glycomacropeptide, into the formula milk powder for pregnant and lying-in women, so that the content of the casein glycomacropeptide in the formula milk powder for pregnant and lying-in women is remarkably higher than that of the existing milk powder for pregnant and lying-in women (only containing trace casein glycomacropeptide contained in cow milk per 100g of milk powder, and the content of the casein glycomacropeptide in each 100g of milk powder is only 0.005g-0.05g), the immunity of the pregnant and lying-in women can be enhanced, the intestinal micro-ecological health of the pregnant and lying-in women can be promoted, and the health of the pregnant and lying-.
In addition, due to the fact that the milk powder is rich in sialic acid, the formula milk powder for pregnant and lying-in women contains enough sialic acid, the content of the sialic acid is far higher than that of the existing milk powder for pregnant and lying-in women, and the sufficient sialic acid is beneficial to promoting intelligence development and growth development of infants. In daily diet of pregnant and lying-in women, the intake of sialic acid is uncontrollable, and due to insufficient cognition, the existing milk powder for pregnant and lying-in women only contains trace sialic acid contained in milk powder raw material milk, and the sialic acid content is low (lower than 0.1g/100 g). Therefore, the pregnant and lying-in woman formula milk powder with high sialic acid content provided by the invention has important significance, and is beneficial to ensuring that a pregnant woman takes in sufficient sialic acid and promoting intelligence development and growth development of infants.
Meanwhile, oligosaccharide is added in combination with casein glycomacropeptide, so that on one hand, the oligosaccharide can promote the intestinal microecological health of pregnant women; on the other hand, researches show that sialic acid exists in breast milk in a form of mainly combining with oligosaccharide (in human milk, 73% of sialic acid is combined with oligosaccharide, 23.7% of sialic acid is combined with protein, 2.9% of sialic acid exists in a free radical form, and 0.4% of sialic acid is combined with lipid).
The invention discovers for the first time that the CGMP has obvious promotion effect on the body health of pregnant and lying-in women and the growth and development of fetuses and infants. A certain amount of casein glycomacropeptide and oligosaccharide are added into the daily ration of the sow in the later stage of pregnancy, so that the health of the sow and the growth and development of offspring are facilitated: it has obvious influence on the reproductive performance of sows, the production performance of weaned piglets and the umbilical cord blood components of sows; has certain influence on the quality of the sow colostrum and normal milk; and the prevobacterium (Prevolla) and the clostridium (Fusobacterium) in the excrement of the sow are obviously higher than those in a control group, which indicates that the flora structure of the gastrointestinal tract of mammals is changed by oligosaccharide and casein glycomacropeptide, and the GOS and the CGMP can improve the reproductive performance of the sow by influencing the abundance of the Prevotella (Prevolella) in the intestinal tract.
(2) According to the formula milk powder for pregnant and lying-in women provided by the embodiment of the invention, a large amount of experimental exploration is carried out on the addition amount of casein glycomacropeptide and oligosaccharide, and finally the proportion and the content of sialic acid and oligosaccharide in the formula milk powder for pregnant and lying-in women are determined (the daily intake of sialic acid is insufficient when the addition amount of casein glycomacropeptide is small, the functional action of casein glycomacropeptide cannot be well exerted, a certain harm is also brought to human bodies when the addition amount of casein glycomacropeptide is excessive, the oligosaccharide and the formula milk powder for pregnant and lying-in women have the same principle), so that the two can fully exert effects, and the obtained formula milk powder for pregnant and lying-in.
(3) The formula milk powder for pregnant and lying-in women provided by the embodiment of the invention scientifically matches the components of the formula milk powder for pregnant and lying-in women, and the obtained formula milk powder for pregnant and lying-in women has balanced nutrition and good effect.
(4) According to the formula milk powder for pregnant and lying-in women provided by the embodiment of the invention, the raw material of GOS is lactose, and the raw material of FOS is sucrose or inulin; GOS is naturally contained in breast milk and is more suitable for the mother-infant population, and therefore, it is preferable to add GOS. The content of GOS in the formula milk powder for pregnant and lying-in women is obviously higher than that of the existing milk powder for pregnant and lying-in women (the content of GOS is less than 1g/100 g).
(5) According to the preparation method of the formula milk powder for pregnant and lying-in women, provided by the embodiment of the invention, the casein glycomacropeptide and the oligosaccharide are added by adopting a wet adding process, so that the casein glycomacropeptide and the oligosaccharide are uniformly mixed.
(6) According to the preparation method of the formula milk powder for the pregnant and lying-in women, provided by the embodiment of the invention, other auxiliary materials except DHA are added by a wet method, so that the mixing uniformity of the auxiliary materials is ensured; DHA is added in a dry mixing way, so that the flavor of the product can be ensured.
Drawings
One or more embodiments are illustrated by the corresponding figures in the drawings, which are not meant to be limiting. The word "exemplary" is used exclusively herein to mean "serving as an example, embodiment, or illustration. Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments.
FIG. 1 shows the abundance of intestinal flora in sows in the lower dose group and the control group using a 16s sequencing method in an example of the effect of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are a part of the embodiments of the present invention, but not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. Throughout the specification and claims, unless explicitly stated otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or component but not the exclusion of any other element or component.
Furthermore, in the following detailed description, numerous specific details are set forth in order to provide a better understanding of the present invention. It will be understood by those skilled in the art that the present invention may be practiced without some of these specific details. In some embodiments, materials, elements, methods, means, and the like that are well known to those skilled in the art are not described in detail in order to not unnecessarily obscure the present invention.
Example 1
1. The formula milk powder for the pregnant and lying-in women is prepared by taking raw milk as a main raw material and adding casein glycomacropeptide and oligosaccharide; every 100g of the pregnant and lying-in women formula milk powder comprises: sialic acid 0.3g, galacto-oligosaccharide 6g, nicotinic acid 5.6mg, folic acid 986 μ g, vitamin A600 μ g, vitamin D6.0 μ g, vitamin K40.0 μ g, vitamin B11 mg, DHA 37.0 mg.
Wherein the CGMP is prepared from Ara Foods Ingredients
CGMP-10, the specific composition of which is shown in Table 1;
the content of Casein Glycomacropeptide (CGMP) in CGMP-10 is 70% -80%, and is adjusted during preparation process
Adding CGMP-10 to obtain milk powder with sialic acid content of 0.3g per 100 g; in the embodiment, every 100g of the formula milk powder for pregnant and lying-in women comprises about CGMP3.5g.
TABLE 1
The content of sialic acid and galacto-oligosaccharide in the formula milk powder for pregnant and lying-in women is measured by sending the formula milk powder for pregnant and lying-in women to the comprehensive detection center of China institute of quarantine science. The contents of nutrient components such as nicotinic acid, folic acid, vitamins and the like are measured by the comprehensive detection center of the Chinese inspection and quarantine scientific research institute.
The total nutrient components of the formula milk powder for pregnant and lying-in women are shown in the table 2:
TABLE 2 nutritional ingredients
2. The formula milk powder for pregnant and lying-in women is prepared by the following steps:
selecting qualified suppliers to determine the source of raw milk and then checking and accepting; cleaning milk, adding all ingredients except DHA according to the above formula, homogenizing with a homogenizer under homogenizing pressure of 15Mpa, and breaking large fat globules; sterilizing at 90 deg.C, and concentrating to reach specified concentration; pumping into a spray tower through a high-pressure pump (210-230bar) to evaporate and dry into uniform powder; adding DHA, mixing, and packaging.
Example 2
1. The formula milk powder for the pregnant and lying-in women is prepared by taking raw milk as a main raw material and adding casein glycomacropeptide and oligosaccharide; every 100g of the pregnant and lying-in women formula milk powder comprises: 0.25g of sialic acid, 6g of galacto-oligosaccharide, 5mg of nicotinic acid, 950 ug of folic acid, 500 ug of vitamin A, 5.0 ug of vitamin D, 35.0 ug of vitamin K, 10.9 mg of vitamin B and 30mg of DHA.
The raw materials of casein glycomacropeptide added into the formula milk powder for pregnant and lying-in women are the same as example 1, and the adjustment is carried out in the preparation process
Adding CGMP-10 to obtain milk powder with sialic acid content of 0.25g per 100 g; in the embodiment, every 100g of the formula milk powder for pregnant and lying-in women comprises about CGMP2.5g.
The method for detecting the content of sialic acid and galacto-oligosaccharide in the formula milk powder for pregnant and lying-in women is the same as that in example 1. The method for measuring the content of nutrient components such as nicotinic acid, folic acid, vitamins and the like is also the same as that in example 1.
2. The formula milk powder for pregnant and lying-in women is prepared by the preparation process in the same embodiment 1.
Example 3
1. The formula milk powder for the pregnant and lying-in women is prepared by taking raw milk as a main raw material and adding casein glycomacropeptide and oligosaccharide; every 100g of the pregnant and lying-in women formula milk powder comprises: 0.4g of sialic acid, 6g of galacto-oligosaccharide, 5mg of nicotinic acid, 950 ug of folic acid, 500 ug of vitamin A, 5.0 ug of vitamin D, 35.0 ug of vitamin K, 10.9 mg of vitamin B and 30mg of DHA.
The raw materials of casein glycomacropeptide added into the formula milk powder for pregnant and lying-in women are the same as example 1, and the adjustment is carried out in the preparation process
Adding CGMP-10 to obtain milk powder with sialic acid content of 0.4g per 100 g; in this embodiment, every 100g of the pregnant and lying-in womenThe formula milk powder comprises CGMP5 g.
The method for detecting the content of sialic acid and galacto-oligosaccharide in the formula milk powder for pregnant and lying-in women is the same as that in example 1. The method for measuring the content of nutrient components such as nicotinic acid, folic acid, vitamins and the like is also the same as that in example 1.
2. The formula milk powder for pregnant and lying-in women is prepared by the preparation process in the same embodiment 1.
Examples of effects
The effect of the maternal and maternal formula milk powder of the above examples was tested as follows.
1. Influence of functional ingredients with different dosages on body condition and reproductive performance of sows in the later stage of pregnancy when the sows are fed with the functional ingredients
(1) Control group: feeding common corn and soybean meal daily ration every day.
Formulations used in experimental groups (including low and high dose groups): functional ingredients (casein glycomacropeptide and galactooligosaccharides) are added into common corn soybean meal daily ration, so that the total daily dosage of the functional ingredients (sialic acid and galactooligosaccharides with the mass ratio of 1: 20) for the sow after conversion is 10 g/kg/day (low dosage group) and 20 g/kg/day (high dosage group)
(2) Experimental methods and results
Functional ingredients with different dosages are added into the daily ration of the sow according to the low dose group, the high dose group and the control group, and the sow is fed for 114 days from the 80 th day of pregnancy.
The results of the influence on the body condition and reproductive performance of sows are shown in Table 3. As can be seen from Table 3, the functional ingredient had no significant effect on the body condition of the sows in the late gestation period, particularly, no significant difference in weight change (p > 0.05) among the sows in each group.
But the functional ingredients have obvious influence on litter performance of the sows, and the specific expression is as follows: the number of born alive young is obviously higher in the low-dose group than in the control group (14.78 +/-0.32 vs 12.82 +/-0.35, p is less than 0.05), and the number of born alive young can be improved in the high-dose group but does not reach a significant level (13.13 +/-0.44 vs 12.82 +/-0.35, p is more than 0.05);
the number of healthy beats in the low-dose group is also obviously higher than that in the control group (14.33 +/-0.41 vs 11.82 +/-0.35, p is less than 0.05), and the number of healthy beats in the high-dose group can be increased but does not reach a significant level (12.25 +/-0.45 vs 11.82 +/-0.35, p is more than 0.05);
there were no significant differences in IUGR numbers (intrauterine growth restriction) and number of dead births between the three groups;
in addition, the offspring primary litter weight (21.24 + -0.91 kg vs 17.81 + -0.42 kg, p < 0.05) and average individual weight (1.52 + -0.04 kg vs 1.40 + -0.04 kg, p < 0.05) in the low dose group were significantly higher than in the control and high dose groups;
the offspring in-pit primary weight variation was also minimal in the low dose group (12.91 + -1.45 kg), significantly lower than the control (18.27 + -1.89 kg, p < 0.05) and high dose groups (17.42 + -0.82 kg, p < 0.05).
In conclusion, the addition of the functional ingredients has a significant influence on the reproductive performance of the sows.
Table 3 influence of functional ingredient added to sow ration in late gestation period (80-114d) on sow reproductive performance (n ═ 11)
2. Influence of low-dose functional ingredients on production performance of weaned piglets when sows in later gestation period are fed with the functional ingredients
The performance data for weaned pigs fed with the functional formula at low doses during the late gestation period (i.e. low dose group) are shown in table 4.
As can be seen from Table 4, the average body weight of the offspring at weaning 1 day, 7 days, 14 days and 21 days was significantly higher than that of the control group, i.e., 1.52. + -. 0.04kg vs 1.40. + -. 0.04, 2.58. + -. 0.08kg vs 2.33. + -. 0.07kg, 4.22. + -. 0.13kg vs 3.60. + -. 0.17kg and 6.29. + -. 0.12kg vs 5.48. + -. 0.21kg (p < 0.05).
Also, the average daily gain was significantly higher in the offspring of the low dose group at 1 and 2 weeks than in the control group, 161.94 + -8.52 g vs 131.94 + -6.90 g, 234.58 + -9.79 g vs 195.95 + -14.69 g (p < 0.05), respectively (Table 4).
In conclusion, the addition of the functional ingredients has a significant influence on the production performance of the weaned piglets.
Table 4 influence of functional ingredient added to sow ration in late gestation period on weaned pig productivity (n ═ 11)
3. The effect of low dosage functional ingredients on colostrum and normal milk when feeding sows at late gestation
The data show that the low dose group is more effective, and therefore, the low dose group was further studied, and the composition of colostrum and normal milk in the low dose group sows is shown in table 5.
As can be seen from table 5, the colostrum of the sow in the low dose group has higher contents of milk fat, milk protein and lactose than the control group, but does not reach a significant level; the milk components (milk fat, milk protein and lactose) in the normal milk of the two groups of sows on day 7 after delivery were also not significantly different.
In conclusion, the addition of the functional ingredients of the low-dose group has certain influence on the quality of the sow colostrum and the normal milk.
Table 5 influence of functional ingredient added to sow ration in late gestation period on colostrum and milk components (n ═ 11)
4. Influence of low-dose functional ingredients on biochemical indexes of umbilical cord blood of sows when sows in later gestation period are fed
The results of biochemical index analysis of the umbilical cord blood of the sows in the low-dose group and the control group show that: the IgA level (1.16 +/-0.07 g/L vs 0.96 +/-0.06 g/L, p < 0.05) and IGF-1 level (59.13 +/-2.30 ng/mL vs 53.45 +/-0.42 ng/mL, p < 0.05) of the umbilical cord blood of the low-dose group sow are obviously higher than those of the control group. The blood sugar level of the umbilical cord blood of the sow in the low-dose group is 0.13 +/-0.02 mmol/L, and has no significant difference with that of a control group (0.08 +/-0.02 mmol/L) (Table 6).
In conclusion, the addition of the functional ingredient in the low dose group had a significant effect on the umbilical cord blood of the sows.
TABLE 6 influence of functional ingredient added in late gestation period on biochemical index of sow umbilical cord blood (n ═ 11)
5. Fecal flora enrichment in low-dose and control sows
The enrichment of the intestinal flora of sows in the lower dose and control groups was determined by 16s sequencing (fig. 1). In the research, after the mother body of the sow in the later gestation period is supplemented with GOS and CGMP, the fecal flora structure is obviously changed, and the characteristics are as follows: the abundance of Protella (Prevotella) and Clostridium (Fusobacterium) increased significantly. The research shows that the Proteobacteria is obviously related to the reproductive performance improvement and the fatty acid biosynthesis, and the experimental data also shows that the reproductive performance of the sow is obviously improved after the sow is supplemented with GOS and CGMP in the later gestation period. Therefore, GOS and CGMP may improve reproductive performance of sows by affecting the abundance of purothuria (Prevotella) in their intestines.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (10)
1. A formula milk powder for pregnant and lying-in women is characterized in that: every 100g of the pregnant and lying-in women formula milk powder comprises: 4-9g of oligosaccharide and 1-7g of casein glycomacropeptide.
2. Maternal formula milk powder according to claim 1, characterized in that: every 100g of the pregnant and lying-in women formula milk powder comprises: 5-7g of oligosaccharide and 2.5-5g of casein glycomacropeptide;
optionally, every 100g of the maternal formula milk powder comprises: 6g of oligosaccharide and 3-4g of casein glycomacropeptide.
3. Maternal formula milk powder according to claim 1, characterized in that: every 100g of the pregnant and lying-in women formula milk powder comprises: sialic acid 0.25-0.4 g; alternatively 0.3 g.
4. Maternal formula milk powder according to claim 3, characterized in that: the oligosaccharide comprises one or more of galacto-oligosaccharide or fructo-oligosaccharide; optionally, the oligosaccharide is a galactooligosaccharide.
5. Maternal formula milk powder according to claim 4, characterized in that: every 100g of the pregnant and lying-in women formula milk powder comprises: 0.25-0.4g of sialic acid and 4-9g of galacto-oligosaccharide; optionally, comprising: sialic acid 0.3g, galacto-oligosaccharide 6 g.
6. Maternal formula milk powder according to claim 1, characterized in that: every 100g of the pregnant and lying-in women formula milk powder also comprises: nicotinic acid, folic acid, vitamin A, vitamin D, vitamin K, vitamin B1, docosahexaenoic acid; optionally, every 100g of the maternal formula milk powder further comprises: 5-6mg of nicotinic acid, 1000 mu g of folic acid 950-; further optionally, every 100g of the maternal formula milk powder, the maternal formula milk powder further comprises: 5.6mg of nicotinic acid, 986 mu g of folic acid, 600 mu g of vitamin A, 6.0 mu g of vitamin D, 40.0 mu g of vitamin K, 11 mg of vitamin B and 37mg of docosahexaenoic acid.
7. Maternal formula milk powder according to claim 6, characterized in that: the formula milk powder for pregnant and lying-in women comprises the following total nutrient components:
8. a method for preparing a powdered formula for pregnant and lying-in women according to any one of claims 1 to 5, wherein the powdered formula comprises: the preparation method comprises the following steps: the formula milk powder for pregnant and lying-in women is prepared by taking components including raw milk as raw materials and adding casein glycomacropeptide and oligosaccharide through a wet processing technology.
9. A method for preparing a powdered formula for pregnant and lying-in women according to any one of claims 6 to 7, wherein the powdered formula comprises: the preparation method comprises the following steps: the components including raw milk are used as raw materials, and the pregnant and lying-in women formula milk powder is prepared by a processing technology of wet method and dry method; wherein the docosahexaenoic acid is added by a dry process, and the other ingredients are added by a wet process.
10. The method of claim 9, wherein: the preparation method comprises the following steps:
checking and accepting the raw milk; feeding all ingredients except docosahexaenoic acid; homogenizing with homogenizer at 4-18 MPa; sterilizing at 85-97 deg.C, and concentrating; spray drying to obtain powder; adding docosahexaenoic acid into the obtained powder, and mixing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010213040.XA CN113068747A (en) | 2020-03-24 | 2020-03-24 | Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010213040.XA CN113068747A (en) | 2020-03-24 | 2020-03-24 | Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113068747A true CN113068747A (en) | 2021-07-06 |
Family
ID=76609346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010213040.XA Pending CN113068747A (en) | 2020-03-24 | 2020-03-24 | Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113068747A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115708530A (en) * | 2022-11-15 | 2023-02-24 | 北大荒完达山乳业股份有限公司 | Pregnant and lying-in woman formula milk powder capable of promoting digestive comfort and stabilizing blood sugar and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10117728A (en) * | 1996-10-25 | 1998-05-12 | Snow Brand Milk Prod Co Ltd | Calcium absorption promoter |
| CN1802094A (en) * | 2003-04-14 | 2006-07-12 | 布里斯托尔-迈尔斯斯奎布公司 | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN101076260A (en) * | 2004-10-13 | 2007-11-21 | 布里斯托尔-迈尔斯斯奎布公司 | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN110881526A (en) * | 2019-11-29 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | Composition for promoting iron absorption and application thereof |
-
2020
- 2020-03-24 CN CN202010213040.XA patent/CN113068747A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10117728A (en) * | 1996-10-25 | 1998-05-12 | Snow Brand Milk Prod Co Ltd | Calcium absorption promoter |
| CN1802094A (en) * | 2003-04-14 | 2006-07-12 | 布里斯托尔-迈尔斯斯奎布公司 | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN101076260A (en) * | 2004-10-13 | 2007-11-21 | 布里斯托尔-迈尔斯斯奎布公司 | Compositions and methods of formulation for enteral formulas containing sialic acid |
| CN110881526A (en) * | 2019-11-29 | 2020-03-17 | 内蒙古伊利实业集团股份有限公司 | Composition for promoting iron absorption and application thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115708530A (en) * | 2022-11-15 | 2023-02-24 | 北大荒完达山乳业股份有限公司 | Pregnant and lying-in woman formula milk powder capable of promoting digestive comfort and stabilizing blood sugar and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011224220C1 (en) | Maternal sialic acid supplementation | |
| Xie et al. | Supplementation of the sow diet with chitosan oligosaccharide during late gestation and lactation affects hepatic gluconeogenesis of suckling piglets | |
| KR20200032048A (en) | Use of lactic acid bacteria to treat or prevent at least one of postpartum depression and postpartum anxiety | |
| RU2495668C2 (en) | Sialic acid for assisted saliva flow | |
| CN112351693A (en) | Anti-influenza virus agent for inhibiting severe influenza | |
| CN112533494A (en) | Treatment or prevention of gestational diabetes using polar lipids | |
| EP2468284A1 (en) | Method of improving immune function in mammals using Lactobacillus strains with certain lipids | |
| US20200397861A1 (en) | Process of preparation of glycan compositions & uses thereof | |
| CN113068747A (en) | Pregnant and lying-in woman formula milk powder for promoting health of pregnant and lying-in women and infants | |
| JP7092380B2 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes | |
| JP6177310B2 (en) | Promotion of infant growth | |
| EP3530281A1 (en) | New process of preparation of glycan compositions & uses thereof | |
| RU2769989C2 (en) | Beta-caseins and intestinal microbiota | |
| WO2021189249A1 (en) | Maternal formula milk powder promoting maternal and infant health | |
| JPWO2007144943A1 (en) | Immune function enhancing composition | |
| Ogra et al. | Human milk | |
| WO2017126645A1 (en) | Composition for inhibiting migration of endotoxin into blood | |
| Lis-Kuberka et al. | The significance of fucosylated glycoconjugates of human milk in nutrition of newborns and infants | |
| Jang | Postnatal Growth and Intestinal Health of Pigs Through Nutritional Intervention | |
| Avery | Direct vs. indirect effects of bioactive milk proteins on neonatal growth: implications for failure to thrive and obesity | |
| CN112806577B (en) | Prebiotic probiotic synergistic combinations for butyric acid production | |
| ES2929638T3 (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| US20240100075A1 (en) | Synthetic Compositions Comprising LNFP III and LSTa | |
| Jahan et al. | The Potential for Sialic Acid and Sialylated Glycoconjugates as Feed Additives to Enhance Pig Health and Production. Animals 2021, 11, 2318 | |
| CN113133531A (en) | Compound protein supplement and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Chen Lijun Inventor after: Zhao Junying Inventor after: Zhang Zhenzhen Inventor after: Fang Xinping Inventor after: Qiao Weicang Inventor after: Li Chaoxu Inventor after: Liu Bin Inventor after: Liu Yanpin Inventor after: Zhou Weiming Inventor before: Chen Lijun Inventor before: Zhao Junying Inventor before: Zhang Zhenzhen Inventor before: Fang Xinping Inventor before: Qiao Weicang Inventor before: Li Xiaoxu Inventor before: Liu Bin Inventor before: Liu Yanpin Inventor before: Zhou Weiming |
|
| CB03 | Change of inventor or designer information |